BioNexus Gene Lab Corp.
BGLCBasic MaterialsNASDAQSpecialty Chemicals
Scan Results
Daily timeframeBioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and. The company carries a $3.5M market cap, placing it firmly in the micro-cap category. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding.
Market Cap
$3.5M
Beta
2.20
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-1.25
EPS (Fwd)
—
ROE
-33.7%
ROA
-19.0%
Cash
$3.5M
Total Debt
$323,197
Free CF
$68,315
52W Change
-76.5%
Annual Financials
Cash vs Debt
Where BGLC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BGLC finished 33.51% below its 150-day moving average ($1.85) and 41.15% below its 200-day moving average ($2.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BGLC overbought or oversold?
At the October 20, 2026 close, BGLC's RSI(14) was 47.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
BioNexus Gene Lab Corp. holds $3.5M in cash against $323K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $68K in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -33.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $10.9M (2022) to $7.4M (2025), a 32% decline worth watching.
A beta of 2.20 means BGLC is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing BGLC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.